Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.

导出 LinkOut

翻译打印收藏纠错

作者： Sven,Stengel ^[1] ; Kevin R,Petrie ^[2] ; Yordan,Sbirkov ^[3] ; Clara,Stanko ^[4] ; Faezeh,Ghazvini Zadegan ^[5] ; Veronica,Gil ^[6] ; Rafał,Skopek ^[5] ; Paweł,Kamiński ^[6] ; Łukasz,Szymański ^[7] ; Annamaria,Brioli ^[8] ; Arthur,Zelent ^[9] ; Tino,Schenk ^[10]

作者单位： Division of Gastroenterology, Hepatology and Infectious Diseases, Department of Internal Medicine IV, Jena University Hospital, Jena, Germany. ^[1] School of Medicine, Faculty of Health Sciences and Wellbeing University of Sunderland, Sunderland, UK. ^[2] Medical University of Plovdiv, Plovdiv, Bulgaria. ^[3] Research Institute at Medical University of Plovdiv, Plovdiv, Bulgaria. ^[4] Department of Hematology and Medical Oncology, Clinic of Internal Medicine II, Jena University Hospital, Jena, Germany. ^[5] Institute of Molecular Cell Biology, CMB, Jena University Hospital, Jena, Germany. ^[6] The Institute of Cancer Research, London, UK. ^[7] The Royal Marsden NHS Foundation Trust, Sutton, UK. ^[8] Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science, Magdalenka, Poland. ^[9] Department of Gynecology and Oncological Gynecology, Military Institute of Medicine, Warsaw, Poland. ^[10] Clinic of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation and Palliative Care, Greifswald University Medicine, Greifswald, Germany. ^[11]

关键词 MYC protein kinase B (AKT) BEZ235 acute myeloid leukaemia all-trans retinoic acid dactolisib leukaemia mammalian target of rapamycin phosphatidylinositol-3 kinase phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PAM)